PCORnet® Study Publications
Currently, there are 65 PCORnet® Studies. Listed below are 28 PCORnet® Studies with primary results publications. Although some studies may have generated additional articles, these publications specifically address the central research questions each study was designed to answer. Up to three primary results publication citations are included for each study.
Search PCORnet® Study publications or filter by therapeutic area.
PCORnet®: Accelerating Patient-Centered Comparative Clinical Effectiveness Research
A special February 2026 PCORI-sponsored supplement of the journal Medical Care looks at the scope and scale of PCORnet.
| PCORnet® Study | Research Question(s) | Citation(s) |
|---|---|---|
|
Advancing Public Health Use of Electronic Health Record Data
Therapeutic Area:
Infectious Disease
|
Research Question(s): |
Zhang, Y., Romieu-Hernandez, A., Boehmer, T.K. et al. Association between SARS-CoV-2 infection and select symptoms and conditions 31 to 150 days after testing among children and adults. BMC Infect Dis 24, 181 (2024). https://doi.org/10.1186/s12879-024-09076-8 Jackson SL, Lekiachvili A, Block JP, et al. Preventive Service Usage and New Chronic Disease Diagnoses: Using PCORnet Data to Identify Emerging Trends, United States, 2018-2022. Prev Chronic Dis. 2024 Jul 3;21:E49. doi: 10.5888/pcd21.230415 Ghildayal N, Nagavedu K, Wiltz JL, et al. Public Health Surveillance in Electronic Health Records: Lessons From PCORnet. Prev Chronic Dis. 2024 Jul 11;21:E51. doi: 10.5888/pcd21.230417 |
|
Comparative Effectiveness of Prophylactic ICD versus Non-ICD Therapy in Contemporary Heart Failure Patients with a Low Risk for Arrhythmic Death (CONTEMP-ICD)
Therapeutic Area:
Cardiovascular
|
Research Question(s): |
Goldenberg I, Zareba W, Ezekowitz JA, et al. Rationale and design of the comparative effectiveness of ICD vs non-ICD therapy in contemporary heart failure patients at a low risk for arrhythmic death (CONTEMP-ICD) trial. Am Heart J. 2026;291:162-174. doi:10.1016/j.ahj.2025.08.020 Goldenberg I, Ezekowitz J, Albert C, et al. Reassessing the need for primary prevention implantable cardioverter defibrillators in contemporary patients with heart failure. Heart Rhythm. 2025;22(4):1040-1051. doi:10.1016/j.hrthm.2024.10.078 |
|
Behavioral Economic and Staffing Strategies to Increase Adoption of the ABCDEF Bundle in the ICU (BEST-ICU)
Therapeutic Area:
Healthcare Delivery
|
Research Question(s): |
Conte M, Schlaeger J, Marsolo K, et al. Computable phenotypes for research using real-world data: experiences from the NIH Pragmatic Trials Collaboratory. J Am Med Inform Assoc. In review. |
|
Measuring Co-creation During the Engagement Process in Research: A Pathway Forward
Therapeutic Area:
Engagement Methods
|
Research Question(s): |
Jolles MP, Willging C, Tufte J, et al. Development and validation of a pragmatic measure of cocreation in research engagement: a study protocol. BMJ Open. 2024;14(12):e091966. |
|
HERO Registry & Trial: Healthcare Worker Exposure Response and Outcomes
Therapeutic Area:
Infectious Disease
|
Research Question(s): |
Friedland A, Hernandez AF, Anstrom KJ, et al. Design of healthcare worker exposure response and outcomes (HERO) research platform. Contemp Clin Trials, 2021; 109:106525. doi.org/10.1016/j.cct.2021.106525 Naggie S, Milstone A, Castro M, et al. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ). Medrxiv, 2021. doi.org/10.1101/2021.08.19.21262275 |
|
PANDA – MSD: Predictive Analytics via Networked Distributed Algorithms for Multi – System Diseases
Therapeutic Area:
Rare Diseases
|
Research Question(s): |
Jian X, Zhang D, Yu Z, et al. Leveraging undecided cases in chart-reviewed phenotypes to enhance EHR-based association studies. J Biomed Inform. 2025;166:104839. doi:10.1016/j.jbi.2025.104839 Tong J, Li L, Reps JM, et al. Advancing Interpretable Regression Analysis for Binary Data: A Novel Distributed Algorithm Approach. Stat Med. 2024;43(29):5573-5582. doi:10.1002/sim.10250 Wu Q, Tong J, Zhang B, et al. Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents. Ann Intern Med. 2024;177(2):165-176. doi:10.7326/M23-1754 |
|
Understanding How Antibiotic Use Affects Childhood Obesity and Growth
Therapeutic Area:
Metabolic Disorders
|
Research Question(s): |
Block JP, Bailey LC, Gillman M, et al. Early Antibiotic Exposure and Weight Outcomes in Young Children. Pediatrics, 2018; 142(6), p.e20180290. doi:10.1542/peds.2018-0290 Heerman WJ, Daley MF, Boone-Heinonen J, et al. Maternal antibiotic use during pregnancy and childhood obesity at age 5 years. Int J Obes (Lond). 2019;43(6):1202-1209. doi:10.1038/s41366-018-0316-6 |
|
Comparing the Benefits and Harms of Three Types of Weight Loss Surgery — The PCORnet® Bariatric Study
Therapeutic Area:
Metabolic Disorders
|
Research Question(s): |
Inge TH, Coley RY., Bazzano LA,. et al. Comparative effectiveness of bariatric procedures among adolescents: the PCORnet bariatric study. SOARD, 2018, 14(9):1374-1386. doi.org/10.1016/j.soard.2018.04.002 McTigue KM, Wellman R, Nauman E, et al. PCORnet Bariatric Study Collaborative. Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass: The National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study. JAMA Surg. 2020;155(5):e200087. doi:10.1001/jamasurg.2020.0087 |
|
Cardiovascular Multicenter Observational Investigation of Lipid Care in the United States-2 (cvMOBIUS2)
Therapeutic Area:
Cardiovascular
|
Research Question(s):Can we reduce the number of people who die from atherosclerotic cardiovascular disease (ASCVD) related deaths by using PCSK9 medicines to lower their cholesterol? |
Navar AM, Shah NP, Shrader P, et al. Achievement of LDL-C <55 mg/dL among US adults: Findings from the cvMOBIUS2 registry. Am Heart J. 2025;279:107-117. doi:10.1016/j.ahj.2024.06.012 Shoji S, Shah NP, Shrader P, et al. Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cvMOBIUS2 registry. Am J Prev Cardiol. 2024;21:100921. Published 2024 Dec 21. doi:10.1016/j.ajpc.2024.100921 |
|
The RECOVER Post-Acute Sequelae of SARS-CoV-2 (PASC) Electronic Health Record (EHR) Cohort Study
Therapeutic Area:
Infectious Disease
|
Research Question(s):
|
Forrest CB, Burrows EK, Mejias A, et al. Severity of Acute COVID-19 in Children <18 Years Old March 2020 to December 2021. Pediatrics. 2022 Apr 1;149(4):e2021055765. doi:10.1542/peds.2021-055765 Rao S, Lee GM, Razzaghi H, et al. Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents. JAMA Pediatr. 2022;176(10):1000. doi:10.1001/jamapediatrics.2022.2800 Bose-Brill S, Hirabayashi K, Schwimmer E, et al; Researching COVID to Enhance Recovery consortium. Pediatric nirmatrelvir/ritonavir prescribing patterns during the COVID-19 pandemic. Hosp Pediatr. 2024;14(8):e341-e348. doi:10.1542/hpeds.2023-007132 |
|
Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term (ADAPTABLE)
Therapeutic Area:
Cardiovascular
|
Research Question: Which dose of daily aspirin offers the right balance of effectiveness and minimal risk of bleeding? Can PCORnet be used to find the answer using a clinical trial model wherein patients are drivers of engagement? |
Marquis-Gravel G, Roe MT, Robertson HR, et al. Rationale and design of the apsirin dosing- a patient-centric trial assessing benefits and long-term effectiveness (ADAPTABLE) Trial. JAMA Cardiol, 2020; 5(5): 598-607. doi:10.1001/jamacardio.2020.0116 Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med, 2021; 384(21); 1981-1990. doi:10.1056/NEJMoa2102137 |
|
Characterization of Patients with Heart Failure and Patients with Atrial Fibrillation and Atrial Flutter in PCORnet Data
Therapeutic Area:
Cardiovascular
|
Research Question(s): |
Rao VN, Cyr D, Wruck L, et al. Electronic health record characterization and outcomes of heart failure with preserved ejection fraction. American Heart Journal. 2023. Vol263, Pg 1-14, ISSN 0002-8703. doi.org/10.1016/j.ahj.2023.04.013 |
|
Using PCORnet to Compare Blood Pressure Control Strategies
Therapeutic Area:
Cardiovascular
|
Research Question(s): |
Cooper-DeHoff RM, Fontil V, Carton T, et al. Tracking blood pressure control performance and process metrics in 25 US health systems: The PCORnet Blood Pressure Control Laboratory. J Am Heart Assoc, 2021; 10(21): e022224. doi:10.1161/JAHA.121.022224 |
|
PCORnet® Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults (PCORnetPASC)
Therapeutic Area:
Infectious Disease
|
Research Question(s):
|
Hernandez-Romieu AC, Carton TW, Saydah S, et al. Prevalence of select new symptoms and conditions among person aged younger than 20 years and 20 years or older at 31 to 150 days after testing positive or negative for SARS-CoV-2. JAMA Netw Open. 2022;5(2):e2147053. doi.org/10.1001/jamanetworkopen.2021.47053 |
|
Comparative Effectiveness of Palliative Surgery vs Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome
Therapeutic Area:
Neurology
|
Research Question(s):
|
Lam S, Rosenman M, Dixon-Salazar D, et al. Comparative effectiveness of epilepsy surgery versus additional anti-seizure medications for Lennox-Gastaut syndrome: study protocol for a multicenter, mixed-methods study. Front Neurol 2025;16:1569551. doi: 10.3389/fneur.2025.1569551 Bliss ND, Patel AD, Dixon-Salazar T, et al. Patient family engagement and partnership: Pilot survey results in assessing behavior, communication, and quality of life in children with Lennox-Gastaut syndrome and other drug-resistant epilepsy. Epilepsy Behav 2023;148:109451. doi: 10.1016/j.yebeh.2023.109451 Votoupal M, Muller R, Patel AD, et al. Navigating the diagnosis: A survey on caregivers’ journeys to Lennox-Gastaut syndrome. Epilepsy Behav 2025;171:110600. doi: 10.1016/j.yebeh.2025.110600 |
|
Empagliflozin Diabetic Kidney Disease (Empa DKD)
Therapeutic Area:
Nephrology
|
Research Question(s):
|
Edmonston, D, Mulder, H, Lydon, E. et al. Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes. JACC. 2024 Aug, 84 (8) 696–708. doi.org/10.1016/j.jacc.2024.06.016 Edmonston D, Mulder H, Lydon E, et al. Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes. Am J Cardiol. 2024;221:52-63. doi:10.1016/j.amjcard.2024.04.011 |
|
Semantic Data Quality Standards for Multi-Center Clinical Research Studies and Networks
Therapeutic Area:
Data Science
|
Research Question(s):
|
Razzaghi H, Dickinson K, Wieand K, et al. A multifaceted approach to advancing data quality and fitness standards in multi-institutional networks. J Am Med Inform Assoc. 2025;ocaf181. doi:10.1093/jamia/ocaf181 |
|
Comparing patient-reported impact of COVID-19 shelter-in-place policies and access to containment and mitigation strategies, overall and in vulnerable populations
Therapeutic Area:
Infectious Disease
|
Research Question(s):
|
Beatty AL, Peyser ND, Butcher XE, et al. The COVID-19 citizen science study: protocol for a longitudinal digital health cohort. JMIR Res Protoc, 2021; 10(8):e28169. doi:10.2196/28169 |
|
Neuroendocrine Tumors – Patient Reported Outcomes (NET-PRO)
Therapeutic Area:
Oncology
|
Research Question(s): Which care options work, for whom, and under which circumstances in order to improve symptom management, treatment outcomes and quality of life among NET patients?
|
Hourcade JP, O’Rorke M, Chrischilles E, et al. Personal Health Record Software for Neuroendocrine Tumors: Patient Centered Design Approach. JMIR Hum Factors. 2025;12:e68788. Published 2025 Jun 3. doi:10.2196/68788 |
|
Outcomes Database to Prospectively Assess Changing Therapy Landscape in Renal Cell Carcinoma (ODYSSEY RCC)
Therapeutic Area:
Oncology
|
Research Question(s): Can a research registry of patients with metastatic renal cell carcinoma (mRCC) patients help us better understand cancer management and health-related quality of life while receiving mRCC specific treatment? In combination with patient and physician surveys, PCORnet will be used to help us answer these questions. |
Bhavsar NA, Harrison MR, Scales CD, et al. Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma. Eur Urol Open Sci. 2024;66:75-81. Published 2024 Jul 3. doi:10.1016/j.euros.2024.06.007 |
|
A Patient-Centered PaTH to Addressing Diabetes
Therapeutic Area:
Metabolic Disorders
|
Research Question(s):
|
Kraschnewski JL, Kong L, Francis E, et al. A Patient-Centered PaTH to Address Diabetes: Protocol for a Study on the Impact of Obesity Counseling. JMIR Res Protoc. 2019 Apr 4;8(4):e12054. doi.org/10.2196/12054 Soleymani T, Lehman EB, Kong L, et al. Bariatric surgery and COVID-19 outcomes: results from the PaTH to Health: Diabetes study. Surg Obes Relat Dis. 2024;20(11):1039-1045. doi:10.1016/j.soard.2024.05.016 |
|
ACTIV-6: COVID-19 Study of Repurposed Medications
Therapeutic Area:
Infectious Disease
|
Research Question(s): |
Naggie SBoulware DRLindsell CJ, et al. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022;328(16):1595–1603. doi:10.1001/jama.2022.18590 McCarthy MW, Naggie S, Boulware DR, et al. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2023;329(4):296–305. doi:10.1001/jama.2022.24100 Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. JAMA. 2023;329(11):888–897. doi:10.1001/jama.2023.1650 |
|
Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA)
Therapeutic Area:
Autoimmune (Allergy and Immunology)
|
Research Question(s): This trial will compare how patients with inactive spondyloarthritis on tumor necrosis factor inhibitor (TNFi) treatment respond to three treatment options that doctors currently use:
|
Weiss PF, Sears CE, Brandon TG, et al. Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA): study protocol for a randomized pragmatic trial. Trials. 2023;24(1):100. Published 2023 Feb 8. doi:10.1186/s13063-022-07038-6 |
|
Pediatric KIDney Stone (PKIDS) Care Improvement Network
Therapeutic Area:
Nephrology
|
Research Question(s): |
Ellison JS, Lorenzo M, Beck H on behalf of the Pediatric KIDney Stone Care Improvement Network, et al. Comparative effectiveness of paediatric kidney stone surgery (the PKIDS trial): study protocol for a patient-centred pragmatic clinical trial. BMJ Open 2022;12:e056789. doi:10.1136/bmjopen-2021-056789 |
|
Evaluating the Comparative Effectiveness of Telemedicine in Primary Care: Learning from the COVID-19 Pandemic
Therapeutic Area:
Healthcare Delivery
|
Research Question(s): |
Lin, J.J., Horowitz, C.R., Ancker, J.S. An Urgent Need for Guidelines for Telemedicine Use. J Gen Intern Med 38, 1061–1062 (2023). doi:10.1007/s11606-022-07905-7 Yu J, Andreadis K, Schpero WL, et al. Patient experiences with and preferences for telemedicine relative to in-person care during the COVID-19 pandemic. Telemedicine and e-Health. Published online 2023. doi:10.1089/tmj.2022.0311 Muellers KA, Andreadis K, Ancker JS, et al. Provider and patient experiences of delays in primary care during the early COVID-19 pandemic. Journal for Healthcare Quality. 2023;45(3):169-176. doi:10.1097/jhq.0000000000000380 |
|
Cognitive Behavioral Therapy and Real-Time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA)
Therapeutic Area:
Mental and Behavioral Health
|
Research Question(s): |
Badawy SM, Abebe KZ, Reichman CA, et al. Comparing the effectiveness of education versus digital cognitive behavioral therapy for adults with sickle cell disease: protocol for the cognitive behavioral therapy and real-time pain management intervention for sickle cell via mobile applications (CaRISMA) study. JMIR Res Protoc, 2021; 10(5):e29014. doi:10.2196/29014 |
|
Medications and Weight Gain in PCORnet: The MedWeight Study
Therapeutic Area:
Metabolic Disorders
|
Research Question(s): |
Sun JW, Young JG, Sarvet AL, et al. Comparison of rates of Type 2 Diabetes in adults and children treated with anticonvulsant mood stabilizers. JAMA Netw Open. 2022;5(4). doi:10.1001/jamanetworkopen.2022.6484 Petimar J, Young JG, Yu H, et al. Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study. Ann Intern Med. 2024;177(8):993-1003. doi:10.7326/M23-2742 Lin PD, Rifas-Shiman S, Merriman J, et al. Trends of Antihypertensive Prescription Among US Adults From 2010 to 2019 and Changes Following Treatment Guidelines: Analysis of Multicenter Electronic Health Records. J Am Heart Assoc. 2024;13(9):e032197. doi:10.1161/JAHA.123.032197 |
|
Pragmatic Evaluation of Events and Benefits of Lipid-lowering in Older Adults (PREVENTABLE)
Therapeutic Area:
Cardiovascular
|
Research Question(s): |
Sachs BC, Rapp SR, Kistler CE, et al. The pragmatic evaluation of events and benefits of lipid-lowering in older adults (PREVENTABLE) trial: study design and procedures for cognitive assessment and adjudication. Alzherimers. Dement., 2021; 17(Supp.9). doi.org/10.1002/alz.054022 |